// App-Quantinova.ai

e16022 : Inhibition of the IGF pathway in metastatic castrate resistant prostate cancer (CRPC): Results from a phase II study of OSI-906 (linsitinib).

Researchers

Presenter

  • Jorge A. Garcia

Principal Investigators

  • Paul Elson

  • Matthew M. Cooney

  • Allison Janine Tyler

  • Victoria Rezash

  • Ernest C. Borden

  • Robert Dreicer

Medical Centers

  • University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

  • Cleveland Clinic, Cleveland, OH

  • Cleveland Clinic Foundation, Cleveland, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • C-C Motif Chemokine Ligand 2

  • Circulating endothelial cells

  • Circulating tumor cells

  • Prostate specific antigen

  • Hepatocyte growth factor receptor

  • Interleukin 6

Drug/Treatment

  • DHEA-S

  • Linsitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01533246

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved